Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John G Gerber

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The AIDS Reader|August 2, 2003
Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicityMarshall J Glesby, John G Gerber
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 28, 2003
Therapeutic drug monitoring in the treatment of HIV-infectionJohn G Gerber, Edward P Acosta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2004
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunctionDavid L Wyles, John G Gerber
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 2005
Abacavir pharmacokinetics in hepatic dysfunctionDavid L Wyles, John G Gerber
AIDS Research and Human Retroviruses|August 31, 2002
Position paper on therapeutic drug monitoring of antiretroviral agentsEdward P Acosta, John G Gerber,
Clinical Pharmacokinetics|October 31, 2002
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infectionCarl J Fichtenbaum, John G Gerber
Chirality|November 25, 2003
Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19John G Gerber, Robert J Rhodes, Joseph Gal
Current HIV/AIDS Reports|August 11, 2005
Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugsJennifer J Kiser, Peter L Anderson, John G Gerber
Chirality|January 9, 2004
Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substratesShahrzad Dilmaghanian, John G Gerber, Scott G Filler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 2, 2005
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosingDavid J Back, David M Burger, Charles W Flexner, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The AIDS Reader|August 2, 2003
Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicityMarshall J Glesby, John G Gerber
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 28, 2003
Therapeutic drug monitoring in the treatment of HIV-infectionJohn G Gerber, Edward P Acosta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2004
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunctionDavid L Wyles, John G Gerber
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 2005
Abacavir pharmacokinetics in hepatic dysfunctionDavid L Wyles, John G Gerber
AIDS Research and Human Retroviruses|August 31, 2002
Position paper on therapeutic drug monitoring of antiretroviral agentsEdward P Acosta, John G Gerber,
Clinical Pharmacokinetics|October 31, 2002
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infectionCarl J Fichtenbaum, John G Gerber
Chirality|November 25, 2003
Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19John G Gerber, Robert J Rhodes, Joseph Gal
Current HIV/AIDS Reports|August 11, 2005
Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugsJennifer J Kiser, Peter L Anderson, John G Gerber
Chirality|January 9, 2004
Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substratesShahrzad Dilmaghanian, John G Gerber, Scott G Filler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 2, 2005
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosingDavid J Back, David M Burger, Charles W Flexner, et al.
Pageof 3